Companies get guidance on communicating healthcare economic information.

The article discusses the U.S. Food and Drug Administration (FDA) draft guidance entitled "Drug and Device Manufacturer Communications with Payors, Formulary Committees and Similar Entities-Questions and Answers." Topics include healthcare economic information on DFA-approved products that can help payors in planning future coverage budgets and reimbursements, the Pharmacy and therapeutics (P&T) committees, and cost-effectiveness models.